Quality Transformation Initiative

Overview

The Quality Transformation Initiative (QTI) is intended to set direct and substantial financial incentives for Covered California’s contracted Qualified Health Plan (QHP) issuers to improve the quality of healthcare and to reduce health disparities for Covered California Enrollees and all Californians. Specifically, the QTI focuses on improving care for a small number of clinically important conditions for which there are major opportunities for improvement and established measures in current use.

Measure Set

For Measurement Years 2023-2025, Covered California has identified four clinical areas of focus for improvement and related core measures that will be subject to QTI payments.

QHP issuers will be assessed per product (HMO, PPO, etc.) on the following QTI core measures using reportable measure scores from the Centers for Medicare & Medicaid Services (CMS) Quality Rating System (QRS):

1. Controlling High Blood Pressure (NQF #0018)

2. Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Control (<8.0%) (NQF #0575)

3. Colorectal Cancer Screening (NQF #0034)

4. Childhood Immunization Status (Combo 10) (NQF #0038)

In addition to the QTI core measure set, QHP issuers will report on the following National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) measures for each of its products: Depression Screening and Follow-Up for Adolescents and Adults (DSF) and Pharmacotherapy for Opioid Use Disorder (POD). Covered California intends to include these measures in the QTI core measure set after benchmarks have been established.

Benchmarks and Quality Transformation Initiative Payments

QHP issuers that fail to meet specified measure benchmarks will be required to make Quality Transformation Initiative Payments. For Measurement Year 2023, 0.8% of each QHP issuer’s total gross premium per product is at risk for performance on the QTI Core Measures. The total amount of Quality Transformation Initiative payment at risk will increase to 1.8% of total gross premium per product in Measurement Year 2024, and up to 2.8% for Measurement Year 2025.

QHP issuer performance per product on the QTI core measures will be compared against CMS QRS national percentile benchmarks for each measure. These benchmarks will remain fixed during the 2023-2025 contract period.

QHP issuers must contribute the full per measure amount to the Quality Transformation Initiative if the measure score is below the 25th national percentile benchmark. For each measure score at or above the 25th and up to the 66th national percentile benchmark, the QHP issuer must contribute a per measure payment amount at a declining constant rate. If the measure is at or above the 66th percentile benchmark, the QHP issuer will not be required to make any payments. The full per measure payment amount is divided equally by each reportable measure in the QTI core measure set.

Assessment Timeline

Covered California will assess QHP issuer performance annually in accordance with CMS’ release of QRS measure scores and percentiles. The following is an anticipated timeline for assessing Measurement Year 2023 performance:

• September 2024: QRS final scores confirmed by CMS.

• October 2024: QRS final scores and percentiles released by CMS.

• October to November 2024: Covered California will prepare QTI Performance Assessment Reports and Population Health Investment (PopHI) Directives and release reports to QHP issuers. QHP issuers have 60 days upon receipt of the QTI Performance Assessment reports to dispute the report.

•  January 2025: QHP issuers shall remit QTI Payments.

• February 2025: Population Health Investments begin.

Covered California will follow a similar timeline to assess Measurement Year 2024 and Measurement Year 2025 performance.

QTI PopHI Advisory Council

The Council is a trusted advisory body consisting of stakeholders and subject matter experts selected by Covered California who support successful deployment of PopHIs to improve the quality of healthcare and to reduce health disparities for Covered California enrollees.

• Advise Covered California in the selection of initial Population Health Investments (PopHIs, pronounced “Poppy”)

• Guide and inform program design features of selected PopHIs, such as: member eligibility, program operations, and key performance indicators and evaluation approaches.

• Establish a forum that supports successful deployment of PopHIs through expert and trusted counsel.

The PopHI Advisory Council does not have decision making authority, and Covered California is not bound to adopt any of the PopHI Advisory Council’s recommendations, but the input shared is critical to sculpting both design and implementation.

PopHI Advisory Council Members

• Tomás Aragón, MD, DrPH - Director and State Public Health Officer, California Department of Public Health

• Palav Babaria, MD, MPH - Deputy Director & Chief Quality and Medical Officer, QPHM, Department of Health Care Services

• Corrin Buchanan, MPP - Deputy Secretary for Policy and Strategic Planning, CalHHS

• Tracy M. Imley, MD - Regional Assistant Medical Director, Quality and Clinical Analysis, Southern California Permanente Medical Group

• Amanda Johnson - Deputy Director, State and Population Health Group, CMS Innovation Center

• Ed Juhn, MD, MBA, MPH - Chief Quality Officer, Inland Empire Health Plan

• Julia Logan, MD - Chief Clinical Director, Clinical Policy & Programs Division, CalPERS

• Peter Long, PhD - Executive Vice President, Strategy and Health Solutions, Blue Shield of California

• Bianca Mahmood - Covered California Consumer

• Sarita Mohanty, MD - President and Chief Executive Officer, The SCAN Foundation

• Cary Sanders, MPP - Senior Policy Director, California Pan-Ethnic Health Network

• Kristof Stremikis, MPP, MPH - Director, Market Analysis and Insight, California Health Care Foundation

• Sadena Thevarajah, JD - Managing Director, Health Begins

• Raymond Tsai, MD, MS - Vice President, Advanced Primary Care, Purchaser Business Group on Health